NCT01545388View on ClinicalTrials.gov

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

PHASE3CompletedINTERVENTIONAL
Enrollment

337

Participants

Timeline

Start Date

February 23, 2012

Primary Completion Date

March 12, 2013

Study Completion Date

March 12, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)

DRUG

Metformin

Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks

DRUG

Metformin

Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks

DRUG

Placebo

Placebo to match metformin 250 mg tablets, orally, for 24 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01545388 - Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136) | Biotech Hunter | Biotech Hunter